DK3076949T3 - Fremgangsmåde til isolering af kræftcelle-afledte eksosomer - Google Patents

Fremgangsmåde til isolering af kræftcelle-afledte eksosomer Download PDF

Info

Publication number
DK3076949T3
DK3076949T3 DK14867768T DK14867768T DK3076949T3 DK 3076949 T3 DK3076949 T3 DK 3076949T3 DK 14867768 T DK14867768 T DK 14867768T DK 14867768 T DK14867768 T DK 14867768T DK 3076949 T3 DK3076949 T3 DK 3076949T3
Authority
DK
Denmark
Prior art keywords
cancer cell
derived exosomes
isolating cancer
isolating
exosomes
Prior art date
Application number
DK14867768T
Other languages
English (en)
Inventor
Raghu Kalluri
Sonia Melo
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of DK3076949T3 publication Critical patent/DK3076949T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5063Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068Cell membranes or bacterial membranes enclosing drugs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
DK14867768T 2013-12-04 2014-12-04 Fremgangsmåde til isolering af kræftcelle-afledte eksosomer DK3076949T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361911863P 2013-12-04 2013-12-04
PCT/US2014/068630 WO2015085096A1 (en) 2013-12-04 2014-12-04 Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis

Publications (1)

Publication Number Publication Date
DK3076949T3 true DK3076949T3 (da) 2019-11-25

Family

ID=53274132

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14867768T DK3076949T3 (da) 2013-12-04 2014-12-04 Fremgangsmåde til isolering af kræftcelle-afledte eksosomer

Country Status (13)

Country Link
US (3) US9921223B2 (da)
EP (1) EP3076949B1 (da)
JP (3) JP2017501694A (da)
AU (3) AU2014360344B2 (da)
CA (1) CA2936100A1 (da)
DK (1) DK3076949T3 (da)
HR (1) HRP20192131T1 (da)
HU (1) HUE046489T2 (da)
LT (1) LT3076949T (da)
NZ (1) NZ721720A (da)
SI (1) SI3076949T1 (da)
WO (1) WO2015085096A1 (da)
ZA (1) ZA201604468B (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
WO2006116362A2 (en) 2005-04-25 2006-11-02 The Trustees Of Boston University Structured substrates for optical surface profiling
US11286463B2 (en) 2012-03-08 2022-03-29 Advanced ReGen Medical Technologies, LLC Reprogramming of aged adult stem cells
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
WO2014028862A1 (en) 2012-08-17 2014-02-20 Cornell University Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
RU2018101152A (ru) 2013-03-15 2019-02-21 Борд оф Риджентс, Дзе Юниверсити оф Тексас Систем Использование биогенеза микрорнк в экзосомах для диагностики и лечения
LT3076949T (lt) * 2013-12-04 2019-12-10 Univ Texas Iš vėžinių ląstelių kilusių egzosomų išskyrimo būdas
CR20160307A (es) 2013-12-20 2016-11-08 Advanced Regen Medical Tech Llc Composiciones para la restauración de células y métodos para la preparación y utilización de las mismas
US10772911B2 (en) 2013-12-20 2020-09-15 Advanced ReGen Medical Technologies, LLC Cell free compositions for cellular restoration and methods of making and using same
US10844436B2 (en) * 2014-04-01 2020-11-24 Cornell University Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection
AU2015327812B2 (en) 2014-10-03 2021-04-15 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
WO2016057702A2 (en) 2014-10-07 2016-04-14 Cornell University Methods for prognosing and preventing metastatic liver disease
US11971402B2 (en) 2015-04-24 2024-04-30 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
US11339441B2 (en) * 2015-05-12 2022-05-24 The Research Foundation For The State University Of New York Profiling chemically modified DNA/RNA units for disease and cancer diagnosis
WO2016201064A1 (en) 2015-06-09 2016-12-15 The Board Of Regents Of The University Of Texas System Diagnostic test for early stage cancer
NZ738149A (en) 2015-06-10 2024-02-23 Univ Texas Use of exosomes for the treatment of disease
EP4343311A2 (en) 2015-09-22 2024-03-27 Trustees of Boston University Multiplexed phenotyping of nanovesicles
GB201518466D0 (en) * 2015-10-19 2015-12-02 Cizzle Biotechnology Ltd Use
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
WO2017136676A1 (en) 2016-02-05 2017-08-10 Nanoview Diagnostics Inc. Detection of exosomes having surface markers
EP3430024A4 (en) * 2016-03-15 2019-11-13 Codiak BioSciences, Inc. THERAPEUTIC MEMBRANE VESICLES
BR112018072198A2 (pt) 2016-04-29 2019-02-12 Advanced ReGen Medical Technologies, LLC composição compreendendo micrornas, método de preparação de uma composição de célula-tronco restaurada, formulação farmacêutica e kit
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
AU2017280204A1 (en) * 2016-06-21 2019-01-24 Nant Holdings Ip, Llc Exosome-guided treatment of cancer
CN106124282B (zh) * 2016-07-26 2019-07-16 广州海力特生物科技有限公司 一种叠层离心过滤分离提取外泌体的方法
US20180067121A1 (en) * 2016-09-06 2018-03-08 Nanoco Technologies Ltd. Exosome-conjugated quantum dot nanoparticles and methods of detecting exosomes and cancer using same
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
US11629176B2 (en) 2017-03-21 2023-04-18 Exoprother Medical Ltd. Native cell derived vesicles containing tumor suppressor proteins for therapy
GB2560897A (en) 2017-03-23 2018-10-03 Lotvall Jan Tissue-derived extracellular vesicles and their use as diagnostics
AU2018255346B2 (en) 2017-04-19 2024-05-02 Capricor Inc Methods and compositions for treating skeletal muscular dystrophy
CN107338306A (zh) * 2017-07-23 2017-11-10 嘉兴允英医学检验有限公司 一种用于GPC1mRNA表达检测的试剂盒
EP4218775A1 (en) * 2017-08-04 2023-08-02 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles for treatment and prevention of cancer
GB2574785A (en) 2017-09-15 2019-12-25 Jan Loetvall Method and system for identifying membrane proteins on extracellular vesicles
WO2019094692A2 (en) * 2017-11-09 2019-05-16 The Trustees Of The University Of Pennsylvania Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment
WO2019109077A1 (en) * 2017-12-01 2019-06-06 Cornell University Nanoparticles and distinct exosome subsets for detection and treatment of cancer
EP3727351A4 (en) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center MODIFIED EXTRACELLULAR VESICLES FOR IMPROVED TISSUE DELIVERY
EP3731849A4 (en) * 2017-12-28 2021-12-01 Codiak BioSciences, Inc. EXOSOME FOR IMMUNONCOLOGICAL AND ANTI-INFLAMMATORY THERAPY
WO2019143847A1 (en) 2018-01-18 2019-07-25 Advanced ReGen Medical Technologies, LLC Therapeutic compositions and methods of making and using the same
WO2019191429A2 (en) * 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in dna isolated from exosomes
CA3095136A1 (en) * 2018-03-28 2019-10-03 Board Of Regents,The University Of Texas System Use of exosomes for targeted delivery of therapeutic agents
US20210024936A1 (en) * 2018-04-09 2021-01-28 Board Of Regents, The University Of Texas System Therapeutic targeting of oncogenes using exosomes
SG11202009499VA (en) * 2018-05-04 2020-11-27 Sigma Aldrich Co Llc Producing recombinant proteins with reduced levels of host cell proteins
US20210364412A1 (en) 2018-06-01 2021-11-25 NanoView Biosciences, Inc. Compositions, systems, and methods for enhanced label-free and fluorescence - based detection of nanoparticles
EP3654215B1 (en) 2018-11-15 2021-06-30 Sternum Ltd. Applying control flow integrity verification in intermediate code files
US11766484B2 (en) 2019-01-03 2023-09-26 International Business Machines Corporation Exosome vessels for delivery of molecular cargo
US20220113313A1 (en) * 2019-02-01 2022-04-14 NanoView Biosciences, Inc. Systems and methods for vesicle cargo labeling and detection
CA3129250A1 (en) * 2019-02-08 2020-08-13 Board Of Regents, The University Of Texas System Isolation and detection of exosome-associated microbiome for diagnostic and therapeutic purposes
US20220275371A1 (en) * 2019-04-23 2022-09-01 Children's Medical Center Corporation Use of rab7 gtpase (rab7) inhibitors in enhancing permeability of the blood brain barrier (bbb)
JP7462452B2 (ja) * 2020-03-27 2024-04-05 株式会社日立製作所 培養細胞の分化レベルを評価するための評価装置および評価方法、並びに自動細胞培養システム
CN112698033A (zh) * 2020-12-09 2021-04-23 复旦大学附属中山医院 一种血源性外泌体her2的检测方法及其应用
WO2023081099A1 (en) * 2021-11-02 2023-05-11 Daniel Kim Extracellular rna signatures of mutant kras(g12c) cancers
WO2023210644A1 (ja) * 2022-04-26 2023-11-02 国立大学法人東京大学 がん細胞由来細胞外小胞群の単離濃縮方法、分析方法、薬剤選択方法、キット、及び抗がん剤
WO2023215820A1 (en) * 2022-05-06 2023-11-09 The Trustees Of The University Of Pennsylvania Ultrasensitive single extracellular vesicle detection using high throughput droplet digital enzyme-linked immunosorbent assay
WO2024047441A1 (en) * 2022-09-01 2024-03-07 Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud Method for monitoring tumor burden in subjects during therapeutic intervention
WO2024073671A1 (en) * 2022-09-30 2024-04-04 Foundation Medicine, Inc. Systems and methods for processing clinico-genomic data

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
FR2766205B1 (fr) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
KR100519384B1 (ko) * 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
ES2703363T3 (es) * 2008-02-01 2019-03-08 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico y pronóstico de tumores cerebrales
CA2821355A1 (en) * 2011-01-31 2012-08-09 Esoterix Genetic Laboratories, Llc Methods for enriching microparticles or nucleic acids using binding molecules
US9777042B2 (en) * 2011-12-15 2017-10-03 Morehouse School Of Medicine Method of purifying HIV/SIV Nef from exosomal fusion proteins
US9309559B2 (en) * 2013-04-15 2016-04-12 Albert Einstein College Of Medicine, Inc. Simultaneous extraction of DNA and RNA from FFPE tissues
LT3076949T (lt) * 2013-12-04 2019-12-10 Univ Texas Iš vėžinių ląstelių kilusių egzosomų išskyrimo būdas

Also Published As

Publication number Publication date
US20200200755A1 (en) 2020-06-25
JP2017501694A (ja) 2017-01-19
JP2019198327A (ja) 2019-11-21
WO2015085096A1 (en) 2015-06-11
LT3076949T (lt) 2019-12-10
EP3076949A1 (en) 2016-10-12
NZ721720A (en) 2022-04-29
US10598665B2 (en) 2020-03-24
AU2019201290A1 (en) 2019-03-14
AU2014360344B2 (en) 2018-11-29
EP3076949A4 (en) 2017-11-22
HRP20192131T1 (hr) 2020-02-21
EP3076949B1 (en) 2019-09-04
JP2021177760A (ja) 2021-11-18
SI3076949T1 (sl) 2020-01-31
US20180045728A1 (en) 2018-02-15
JP7138372B2 (ja) 2022-09-16
ZA201604468B (en) 2024-01-31
US20170059572A1 (en) 2017-03-02
AU2014360344A1 (en) 2016-07-14
AU2019200573A1 (en) 2019-02-21
US9921223B2 (en) 2018-03-20
CA2936100A1 (en) 2015-06-11
HUE046489T2 (hu) 2020-03-30

Similar Documents

Publication Publication Date Title
DK3076949T3 (da) Fremgangsmåde til isolering af kræftcelle-afledte eksosomer
DK2996556T3 (da) System til billedstyret procedure
DK3126395T3 (da) Multispecifikke antistoffer
DK3611262T3 (da) Fremgangsmåder til sekvensering af immunrepertoire
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK2972353T3 (da) Forbedrede fremgangsmåder til udførelse af multipleksanalyser
DK3544364T3 (da) Indretninger til radioforbindelser
DK3010352T3 (da) Fremgangsmåde til fremstilling af fodertilsætning
DK3013544T3 (da) Fremgangsmåde til betonfremstilling
DK3044788T3 (da) Ikke-uniform parameterkvantificering til avanceret kobling
GB2527235B (en) Privacy masking method
BR112015021083A2 (pt) método
DK3332813T3 (da) Metode til opregulering af antigenekspression
DK2983680T3 (da) Forbedring af organer til transplantation
BR112015029076A2 (pt) método
DK2878528T3 (da) Fremgangsmåde til motordreven landing
DK3065790T3 (da) Fremgangsmåder til fjernelse af alpha-galactose
BR112016002104A2 (pt) método de síntese de 3-oxopent-4-enoil-coa
DK3042205T3 (da) Fremgangsmåde til forbedring af antistofstabilitet
DK2998395T3 (da) Fremgangsmåde til fremstilling af lactaseholdige sammensætninger
DK3016682T3 (da) Metoder til behandling af kræft
DK2752606T3 (da) Kanalsystem
DK3047025T3 (da) Fremgangsmåde til fremstilling af kappevira
DE112013007428A5 (de) Komponententräger
DK2886215T3 (da) Fremgangsmåde til fremstilling af en aluminiumsprofil